ABL, Inc. and CALIXAR Announced Strategic Marketing Agreement

October 1, 2013

ABL will extend the capabilities of its vaccine and biologics therapeutic development services by offering CALIXAR’s innovative process for native extraction and purification of membrane proteins and antigens that avoid the necessity of re

Read the article

Expression of fully native proteins

Identification of relevant targets

Target functional isolation and stabilization

Active custom proteins

Structure-based drug discovery

Immunoassays

Vaccine development

Functional antigen discovery

Conformational antibody development

Expression of fully native proteins

Identification of relevant targets

Target functional isolation and stabilization

Active custom proteins

Structure-based drug discovery

Immunoassays

Vaccine development

Functional antigen discovery

Conformational antibody development

Secure and boost
your discovery programs

Starting from native material or recombinant systems, we succeed with all types of proteins: Kinases, Phosphatases, Ubiquitins, Epigenetic Proteins, GPCRs, Ion Channels, Transporters, Receptors and Viral Proteins.